ArticleCell reports. Medicine2023

L858R emerges as a potential biomarker predicting response of lung cancer models to anti-EGFR antibodies: Comparison of osimertinib vs. cetuximab.

Ilaria Marrocco et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.